ANTI-CD3 ANTIBODIES AND METHODS OF USE

FIELD OF THE INVENTION

The present invention relates to anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.

BACKGROUND

Cell proliferative disorders, such as cancer, are characterized by the uncontrolled growth of cell subpopulations. They are the leading cause of death in the developed world and the second leading cause of death in developing countries, with over 12 million new cancer cases diagnosed and 7 million cancer deaths occurring each year. The National Cancer Institute estimates that greater than half a million Americans will die of cancer in 2013, accounting for nearly one out of every four deaths in the country. As the elderly population has grown, the incidence of cancer has concurrently risen, as the probability of developing cancer is more than two-fold higher after the age of seventy. Cancer care thus represents a significant and ever-increasing societal burden.

Longstanding approaches to cancer treatment include chemotherapy, radiation therapy, and surgery to remove solid tumors. Recently, bispecific antibody-based immunotherapies have been developed. Such bispecific antibodies are capable of simultaneously binding cell surface antigens on cytotoxic cells and tumor cells, with the intent that the bound cytotoxic cell will destroy the bound tumor cell. Existing bispecific antibodies currently undergoing clinical trials for treating cancer are limited by their short half-lives and/or variable efficacy. Thus, there is an unmet need in the field for the development of effective bispecific antibodies for use in cancer treatment.

SUMMARY

The present ~~invention~~disclosure relates to anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.

In one aspect, the disclosure provides an anti-CD3 antibody which is a bispecific antibody, wherein the bispecific antibody comprises:

an anti-CD3 arm comprising a first binding domain comprising the following six hypervariable regions (HVRs):

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7,
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8,
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9,
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10,
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11, and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12; and

an anti-LYPD1 arm comprising a second binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 175,
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 176,
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 177,
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 178,
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 179, and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 180.

In one ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six hypervariable regions (HVRs): (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some ~~embodiment~~examples, the binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 184; (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 185; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 184. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 185. In some ~~embodiment~~examples, the binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID

NO: 186; (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 187; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 186. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 187.

In one ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of $X_1X_2YSX_3X_4X_5FDY$, wherein X_1 is selected from the group consisting of D, T, and S; X_2 is selected from the group consisting of G, A, and S; X_3 is R or N; X_4 is Y or A; and X_5 is Y or A (SEQ ID NO: 181); (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of $X_1X_2SX_3X_4LRT$, wherein X_1 is K or T; X_2 is Q or A; X_3 is F or A; and X_4 is I or A (SEQ ID NO: 182). In some ~~embodiment~~examples, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 188; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 189; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 188. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 189.

In other ~~embodiment~~examples, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 13; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 190; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 191; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 190. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 191.

In other ~~embodiment~~examples, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid

sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 192; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 193; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 192. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 193.

In other ~~embodiment~~examples, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 15. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 194; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 195; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 194. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 195.

In other ~~embodiment~~examples, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 16. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 196; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 197; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 196. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 197.

In other ~~embodiment~~examples, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 17; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 198; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 199; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 198. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 199.

In other ~~embodiment~~examples, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid

sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 18; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 200; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 201; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 200. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 201.

In other ~~embodiment~~examples, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 19; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 202; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 203; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 202. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 203.

In other ~~embodiment~~examples, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 20; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 204; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 205; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 204. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 205.

In other ~~embodiment~~examples, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 21; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 22. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 206; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 207; or (c) a VH domain as in (a) and a VL domain as in (b). In some

~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 206. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 207.

In some ~~aspect~~examples, the ~~invention~~disclosure features an anti-CD3 antibody comprising a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 188 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 189; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 190 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 191; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 192 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 193; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 194 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 195; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 196 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 197; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 198 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 199; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 200 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 201; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 202 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 203; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 204 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 205; or (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 206 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 207.

In some ~~aspect~~examples, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23; (b) an HVR-H2 comprising the amino acid sequence of LINPYKGVX_1TY$X_2X_3X_4X_5$KX_6, wherein X_1 is S or T; X_2 is N or A; X_3 is Q or D; X_4 is K or S; X_5 is F or V; and X_6 is D or G (SEQ ID NO: 183); (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28. In some ~~embodiment~~examples, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 24; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 208; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 209; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 208. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 209.

In other ~~embodiment~~examples, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 29; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25; (d)

an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 210; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 211; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 210. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 211.

In other ~~embodiment~~examples, the binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 30; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 212; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 213; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 212. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 213.

In some ~~aspect~~examples, the ~~invention~~disclosure features an anti-CD3 antibody comprising a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 208 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 209; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 210 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 211; or (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 212 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 213.

In some ~~aspect~~examples, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 31; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 32; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 33; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 34; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 35; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 36. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 214; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 215; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 214. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 215. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 216; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 217; or (c) a VH

domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 216. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 217.

In some ~~aspect~~examples, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 214 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 215, or (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 216 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 217.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 37; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 38; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 40; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 41; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 42. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 218; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 219; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 218. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 219. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 220; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 221; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 220. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 221.

In some ~~aspect~~examples, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 218 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 219, or (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 220 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 221.

In some ~~aspect~~examples, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 43; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 44; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 45; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 46; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 47; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 48. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 222; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of

SEQ ID NO: 223; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 222. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 223. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 224; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 225; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 224. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 225. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 226; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 227; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 226. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 227.

In some ~~aspect~~examples, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 222 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 223; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 224 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 225; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 226 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 227.

In some ~~aspect~~examples, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 49; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 50; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 51; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 52; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 54. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 228; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 229; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 228. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 229. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 230; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 231; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 230. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 231.

In some ~~aspect~~examples, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID

NO: 228 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 229, or (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 230 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 231.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 55; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 56; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 57; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 58; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 59; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 60. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 232; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 233; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 232. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 233.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 232 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 233.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 61; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 62; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 63; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 64; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 65; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 66. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 234; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 235; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 234. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 235.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 234 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 235.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 67; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 68; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 69; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 70; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 71; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 72. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence

having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 236; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 237; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 236. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 237.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 236 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 237.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 73; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 74; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 75; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 76; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 77; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 78. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 238; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 239; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 238. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 239.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 238 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 239.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 79; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 80; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 81; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 82; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 83; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 84. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 240; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 241; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 240. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 241.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 240 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 241.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino

acid sequence of SEQ ID NO: 85; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 86; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 87; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 88; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 89; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 90. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 242; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 243; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 242. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 243.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 242 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 243.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 91; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 92; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 93; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 94; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 95; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 96. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 244; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 245; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 244. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 245.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 244 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 245.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 97; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 98; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 99; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 100; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 101; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 102. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 246; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 247; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 246. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 247.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 246 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 247.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 103; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 104; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 105; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 106; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 107; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 108. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 248; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 249; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 248. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 249.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 248 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 249.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 109; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 110; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 111; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 112; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 113; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 114. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 250; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 251; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 250. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 251.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 250 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 251.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 117; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 120. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence

having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 252; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 253; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 252. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 253.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 252 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 253.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 121; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 122; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 123; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 124; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 125; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 126. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 254; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 255; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 254. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 255.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 254 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 255.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 127; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 128; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 129; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 130; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 131; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 132. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 256; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 257; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 256. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 257.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 256 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 257.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino

acid sequence of SEQ ID NO: 133; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 134; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 135; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 136; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 137; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 138. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 258; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 259; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 258. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 259.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 258 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 259.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 139; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 140; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 141; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 142; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 143; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 144. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 260; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 261; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 260. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 261.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 260 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 261.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 145; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 146; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 147; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 148; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 149; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 150. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 262; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 263; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 262. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 263.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 262 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 263.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 151; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 152; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 153; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 154; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 155; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 156. In some ~~embodiment~~examples, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 264; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 265; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 264. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 265.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 264 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 265.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody binds to an epitope on CD3 comprising amino acid residue Glu6 of CD3. In certain ~~aspect~~examples, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the epitope further comprises one or more additional amino acid residues selected from the group consisting of Gln1, Asp2, and Met7 of CD3. In a further ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the epitope comprises amino acid residues Gln1, Asp2, and Glu6 of CD3. In certain ~~aspect~~examples, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the epitope comprises amino acid residues Gln1, Asp2, Glu6, and Met7 of CD3. In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the epitope does not comprise amino acid residue Glu5 of CD3. In a further ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the epitope does not comprise amino acid residues Gly3 and Glu5 of CD3. In certain ~~aspect~~examples, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the epitope consists of amino acid residues Gln1, Asp2, Glu6, and Met7 of CD3.

In related ~~aspect~~examples, the ~~invention~~disclosure features an anti-CD3 antibody that binds such an epitope and that is a multispecific antibody. In some ~~embodiment~~examples, the multispecific antibody is a bispecific antibody. In some ~~embodiment~~examples, the bispecific antibody comprises a second binding domain that binds to a second biological molecule, wherein the second biological molecule is a cell surface antigen. In some ~~embodiment~~examples, the cell surface antigen is a tumor antigen. In some ~~embodiment~~examples, the tumor antigen is selected from the group consisting of CD20; FcRH5 (Fc Receptor-like 5); HER2; LYPD1; Ly6G6D (lymphocyte antigen 6 complex, locus G61); Ly6-D, MEGT1); PMEL17 (silver homolog; SILV; D12S53E; PMEL17; (SI); (SIL); ME20; gp100); Ly6E (lymphocyte antigen 6 complex, locus E; Ly67, RIG-E, SCA-2, TSA-1); CD19; CD33; CD22 (B-cell receptor CD22-B isoform); CD79a (CD79A, CD79a, immunoglobulin-associated alpha; BMPR1B (bone morphogenetic protein receptor-type IB); CD79b (CD79B, CD79β, 1 Gb (immunoglobulin-associated beta), B29); EDAR (Ectodysplasin A Receptor); GFRA1 (GDNF-Ra1);

VEGF; WT1; XAGE-1b/GAGED2a; and SLC53SLC35D3. In some ~~embodiment~~examples, the tumor antigen is selected from the group consisting of CD20, FcRH5, HER2, LYPD1, LY6G6D, PMEL17, LY6E, CD19, CD33, CD22, CD79A, CD79B, EDAR, GFRA1, MRP4, RET, Steap1, and TenB2. In preferred ~~embodiment~~examples, the tumor antigen is selected from the group consisting of CD20, HER2, FcRH5, and LYPD1.

In some ~~embodiment~~examples, the binding domain of any one of the preceding anti-CD3 antibodies binds to a human CD3 polypeptide or a cynomolgus monkey (cyno) CD3 polypeptide. In some ~~embodiment~~examples, the human CD3 polypeptide or the cyno CD3 polypeptide is a human CD3ε polypeptide or a cyno CD3ε polypeptide, respectively. In some ~~embodiment~~examples, the human CD3 polypeptide or the cyno CD3 polypeptide is a human CD3γ polypeptide or a cyno CD3γ polypeptide, respectively.

In some ~~embodiment~~examples, any one of the preceding anti-CD3 antibodies binds the human CD3ε polypeptide with a Kd of 250 nM or lower. In some ~~embodiment~~examples, the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 100 nM or lower. In some ~~embodiment~~examples, the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 15 nM or lower. In some ~~embodiment~~examples, the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 10 nM or lower. In some ~~embodiment~~examples, the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 5 nM or lower.

In some ~~embodiment~~examples, any one of the preceding anti-CD3 antibodies may comprise an aglycosylation site mutation. In some ~~embodiment~~examples, the aglycosylation site mutation is a substitution mutation. In some ~~embodiment~~examples, the substitution mutation is at amino acid residue N297, L234, L235, and/or D265 (EU numbering). In some ~~embodiment~~examples, the substitution mutation is selected from the group consisting of N297G, N297A, L234A, L235A, and D265A. In some ~~embodiment~~examples, the substitution mutation is an N297G mutation. In some ~~embodiment~~examples, the aglycosylation site mutation reduces effector function of the anti-CD3 antibody. In some ~~embodiment~~examples, the aglycosylation site mutation reduces effector function of the anti-CD3 antibody. In some ~~embodiment~~examples, an anti-CD3 antibody comprises a substitution mutation in the Fc region that reduces effector function.

In some ~~embodiment~~examples, any one of the preceding anti-CD3 antibodies can be monoclonal, human, humanized, or chimeric. In some ~~embodiment~~examples, any one of the preceding anti-CD3 antibodies can be an antibody fragment that binds CD3. In some ~~embodiment~~examples, the antibody fragment is selected from the group consisting of Fab, Fab'-SH, Fv, scFv, and $(Fab')_2$ fragments. In other ~~embodiment~~examples, the anti-CD3 antibody is a full-length antibody. In some ~~embodiment~~examples, the anti-CD3 antibody is an IgG antibody (e.g., an IgG1, IgG2, or IgG3 antibody). In some ~~embodiment~~examples, the anti-CD3 antibody is a monospecific antibody. In some ~~embodiment~~examples, the anti-CD3 antibody is a Bispecific T-Cell Engager (BiTE®) antibody).

In some ~~embodiment~~examples, the anti-CD3 antibody is a multispecific antibody. In some ~~embodiment~~examples, the multispecific antibody is a bispecific antibody. In some ~~embodiment~~examples, the bispecific antibody comprises a second binding domain that binds to a second biological molecule, wherein the second biological molecule is a cell surface antigen. In some ~~embodiment~~examples, the cell surface antigen is a tumor antigen. In some ~~embodiment~~examples, the tumor antigen is selected from the group consisting of CD20; FcRH5 (Fc Receptor-like 5); HER2; LYPD1; Ly6G6D (lymphocyte antigen 6 complex, locus G61); Ly6-D, MEGT1); PMEL17 (silver homolog; SILV; D12S53E; PMEL17; (SI); (SIL); ME20; gp100); Ly6E (lymphocyte antigen 6 complex, locus E; Ly67, RIG-E, SCA-2, TSA-1); CD19; CD33; CD22 (B-cell

SNRPD1; SOX10; Sp17; SSX-2; SSX-4; STEAP1; survivin; SYT-SSX1 or -SSX2 fusion protein; TAG-1; TAG-2; Telomerase; TGF-betaRII; TRAG-3; Triosephosphate isomerase; TRP-1 / gp75; TRP-2; TRP2-INT2; tyrosinase; VEGF; WT1; XAGE-1b/GAGED2a; and SLC35D3. In some ~~embodiment~~examples, the tumor antigen is selected from the group consisting of CD20, FcRH5, HER2, LYPD1, LY6G6D, PMEL17, LY6E, CD19, CD33, CD22, CD79A, CD79B, EDAR, GFRA1, MRP4, RET, Steap1, and TenB2.

In some ~~embodiment~~examples, the tumor antigen is CD20 and the second binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 157; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 158; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 159; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 160; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 161; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 162. In some ~~embodiment~~examples, the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 266; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 267; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 266. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 267.

In some ~~embodiment~~examples, the tumor antigen is FcRH5 and the second binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 163; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 164; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 165; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 166; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 167; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 168. In some ~~embodiment~~examples, the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 268; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 269; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 268. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 269.

In some ~~embodiment~~examples, the tumor antigen is HER2 and the second binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 169; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 170; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 171; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 172; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 173; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 174. In some ~~embodiment~~examples, the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 270; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 271; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the

amino acid sequence of SEQ ID NO: 270. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 271.

In some ~~embodiment~~examples, the tumor antigen is HER2 and the second binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 581; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 582; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 583; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 584; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 585; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 586. In some ~~embodiment~~examples, the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 593; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 594; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 593. In some ~~embodiment~~examples the VL domain comprises the amino acid sequence of SEQ ID NO: 594.

In some ~~embodiment~~examples, the tumor antigen is HER2 and the second binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 587; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 588; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 589; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 590; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 591; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 592. In some ~~embodiment~~examples, the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 595; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 596; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 595. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 596.

In some ~~embodiment~~examples, the tumor antigen is RET and the second binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 613; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 614; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 615; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 616; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 617; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 618. In some ~~embodiment~~examples, the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 619; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 620; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~examples, the VH domain comprises the amino acid sequence of SEQ ID NO: 619. In some ~~embodiment~~examples, the VL domain comprises the amino acid sequence of SEQ ID NO: 620.

In some ~~embodiment~~examples, the tumor antigen is LYPD1 and the second binding domain comprises the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 175; (b) an

HVR-H2 comprising the amino acid sequence of SEQ ID NO: 176; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 177; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 178; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 179; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 180. In some ~~embodiment~~example~~s~~, the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 272; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 273; or (c) a VH domain as in (a) and a VL domain as in (b). In some ~~embodiment~~example~~s~~, the VH domain comprises the amino acid sequence of SEQ ID NO: 272. In some ~~embodiment~~example~~s~~, the VL domain comprises the amino acid sequence of SEQ ID NO: 273.

In some ~~aspect~~example~~s~~, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising: (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 268 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 269; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 270 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 271; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 272 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 273; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 593 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 594; (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 595 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 596; or (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 619 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 620.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and an anti-CD20 arm comprising a second binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 157; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 158; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 159; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 160; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 161; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 162.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185, and an anti-CD20 arm comprising a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185, and an anti-CD20 arm comprising a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267, wherein the anti-CD3 antibody comprises an N297G substitution mutation.

In another ~~aspect~~example, the ~~invention~~disclosure features an anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185, and an anti-CD20 arm comprising a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267, wherein (a) the anti-CD3 arm comprises T366S, L368A, Y407V, and N297G substitution mutations and (b) the anti-CD20 arm comprises T366W and N297G substitution mutations.

In some ~~embodiment~~examples, any one of the preceding anti-CD3 antibodies can comprise one or more heavy chain constant domains, wherein the one or more heavy chain constant domains are selected from a first CH1 ($CH1_1$) domain, a first CH2 ($CH2_1$) domain, a first CH3 ($CH3_1$) domain, a second CH1 ($CH1_2$) domain, second CH2 ($CH2_2$) domain, and a second CH3 ($CH3_2$) domain. In some ~~embodiment~~examples, at least one of the one or more heavy chain constant domains is paired with another heavy chain constant domain. In some ~~embodiment~~examples, the $CH3_1$ and $CH3_2$ domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the $CH3_1$ domain is positionable in the cavity or protuberance, respectively, in the $CH3_2$ domain. In some ~~embodiment~~examples, the $CH3_1$ and $CH3_2$ domains meet at an interface between said protuberance and cavity. In some ~~embodiment~~examples, the $CH2_1$ and $CH2_2$ domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the $CH2_1$ domain is positionable in the cavity or protuberance, respectively, in the $CH2_2$ domain. In some ~~embodiment~~examples, the $CH2_1$ and $CH2_2$ domains meet at an interface between said protuberance and cavity.

In some ~~embodiment~~examples, the half-life of any one of the preceding anti-CD3 antibodies may be about 7 days.

In one aspect, the disclosure provides an immunoconjugate comprising the bispecific antibody as disclosed herein and a cytotoxic agent. In some ~~embodiment~~examples, the ~~invention~~disclosure features an immunoconjugate comprising any one of the preceding anti-CD3 antibodies conjugated to a cytotoxic agent. In one aspect, the disclosure provides a composition comprising the bispecific antibody as disclosed herein and a pharmaceutically acceptable carrier, excipient, or diluent. Also provided is a composition comprising any one of the preceding anti-CD3 antibodies. In some ~~embodiment~~examples, the composition further comprises a pharmaceutically acceptable carrier, excipient, or diluent. In some ~~embodiment~~examples, the composition is a pharmaceutical composition. In some ~~embodiment~~examples, the composition further comprises a PD-1 axis binding antagonist or an additional therapeutic agent. In one aspect, the disclosure provides an isolated nucleic acid encoding the bispecific antibody as disclosed herein. In another aspect, the disclosure provides a vector comprising the isolated nucleic acid as disclosed herein. In another ~~aspect~~example, the ~~invention~~disclosure features an isolated nucleic acid that encodes any of the anti-CD3 antibodies disclosed herein, comprising a vector (e.g., an expression vector) for expressing the antibody.

In one aspect, the disclosure provides an isolated host cell comprising the vector as disclosed herein. In another ~~aspect~~example, the ~~invention~~disclosure features host cells comprising the preceding nucleic acids and/or vectors. In some ~~embodiment~~examples, the host cell is a mammalian cell (e.g., a Chinese hamster ovary (CHO) cell). In other ~~embodiment~~examples, the host cell is a prokaryotic cell (e.g., an *E. coli* cell). In one aspect, the disclosure provides a method of producing the bispecific antibody as disclosed herein, the method comprising culturing the host cell as disclosed herein in a culture medium and recovering the bispecific antibody from the host cell or the culture medium. A

method of producing any one of the preceding anti-CD3 antibodies is also provided, the method comprising culturing the host cell that produces the anti-CD3 antibody and recovering the anti-CD3 antibody from the host cell or the culture medium.

In one aspect, the disclosure provides the bispecific antibody as disclosed herein for use as a medicament. In some ~~aspect~~examples, any one of the preceding anti-CD3 antibodies can be for use as a medicament. In one aspect, the disclosure provides the bispecific antibody as disclosed herein for use in (i) treating or delaying progression of a cell proliferative disorder in a subject in need thereof or (ii) enhancing immune function in a subject having a cell proliferative disorder. In some ~~embodiment~~examples, any one of the preceding anti-CD3 antibodies can be for use in treating or delaying progression of a cell proliferative disorder or an autoimmune disorder in a subject in need thereof. In some ~~embodiment~~examples, any one of the preceding anti-CD3 antibodies can be for use in enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder.

In one aspect, the present disclosure provides use of the bispecific antibody as disclosed herein in the manufacture of a medicament. In some ~~aspect~~examples, the ~~invention~~disclosure features the use of any one of the preceding anti-CD3 antibodies in the manufacture of a medicament for treating or delaying progression of a cell proliferative disorder or an autoimmune disorder. In some ~~aspect~~examples, the ~~invention~~disclosure features the use of any one of the preceding anti-CD3 antibodies in the manufacture of a medicament for enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder.

A further ~~aspect~~example of the ~~invention~~disclosure is a method of treating or delaying the progression of a cell proliferative disorder or an autoimmune disorder in a subject in need thereof, the method comprising administering to the subject an effective amount any one of the preceding anti-CD3 antibodies. In another ~~aspect~~example, the ~~invention~~disclosure features a method of enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder, the method comprising administering to the subject any one of the preceding anti-CD3 antibodies. In some ~~embodiment~~examples, the anti-CD3 antibody binds to (a) a CD3 molecule located on an immune effector cell and (b) a second biological molecule located on a target cell other than the immune effector cell. In some ~~embodiment~~examples, the anti-CD3 antibody activates the immune effector cell following binding to (a) and (b). In some ~~embodiment~~examples, the activated immune effector cell is capable of exerting a cytotoxic effect and/or an apoptotic effect on the target cell. In some ~~embodiment~~examples, the anti-CD3 antibody is administered to the subject in a dosage of about 0.01 mg/kg to about 10 mg/kg. In some ~~embodiment~~examples, the anti-CD3 antibody is administered to the subject in a dosage of about 0.1 mg/kg to about 10 mg/kg. In some ~~embodiment~~examples, the anti-CD3 antibody is administered to the subject in a dosage of about 1 mg/kg. In some ~~embodiment~~examples, the anti-CD3 antibody is administered subcutaneously, intravenously, intramuscularly, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally. In some ~~embodiment~~examples, the anti-CD3 antibody is administered subcutaneously. In some ~~embodiment~~examples, the anti-CD3 antibody is administered intravenously.

In some ~~embodiment~~examples, the method further comprises administering to the subject a PD-1 axis binding antagonist or an additional therapeutic agent. In some ~~embodiment~~examples, the additional therapeutic agent is administered prior to or subsequent to the administration of the anti-CD3 antibody. In some ~~embodiment~~examples, the additional therapeutic agent is administered concurrently with the anti-CD3 antibody. In some ~~embodiment~~examples, the PD-1 axis binding antagonist is selected from the group consisting of a PD-1 binding antagonist, a PD-L1 binding antagonist, and a PD-L2 binding antagonist. In some ~~embodiment~~examples, the PD-1 axis binding antagonist is a PD-1 binding antagonist. In some ~~embodiment~~examples, the PD-1 binding antagonist is selected from the group consisting of MDX-1106 (nivolumab), MK-3475 (lambrolizumab), CT-011 (pidilizumab), and AMP-224. In other ~~embodiment~~examples, the PD-1 axis binding antagonist is a PD-L1

binding antagonist. In some ~~embodiment~~examples, the PD-L1 binding antagonist is selected from the group consisting of: YW243.55.S70, MPDL3280A, MDX-1105, and MEDI4736. In other ~~embodiment~~examples, the PD-1 axis binding antagonist is a PD-L2 binding antagonist. In some ~~embodiment~~examples, the PD-L2 binding antagonist is an antibody or an immunoadhesin.

In some ~~aspect~~examples, the ~~invention~~disclosure features a method of treating or delaying the progression of a cell proliferative disorder or an autoimmune disorder in a subject in need thereof, the method comprising administering to the subject an anti-CD3 antibody and a PD-1 axis binding antagonist, wherein the anti-CD3 antibody comprises an anti-CD3 arm and an anti-CD20 arm. In some ~~aspect~~examples, the ~~invention~~disclosure features a method of enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder, the method comprising administering to the subject an anti-CD3 antibody and a PD-1 axis binding antagonist, wherein the anti-CD3 antibody comprises an anti-CD3 arm and an anti-CD20 arm (i.e., a CD20 TDB). In some ~~embodiment~~examples, (a) the anti-CD3 arm comprises a first binding domain comprising (i) a VH domain comprising an amino acid sequence of SEQ ID NO: 184, and (ii) a VL domain comprising an amino acid sequence of SEQ ID NO: 185; (b) the anti-CD20 arm comprises a second binding domain comprising (i) a VH domain comprising an amino acid sequence of SEQ ID NO: 266, and (ii) a VL domain comprising an amino acid sequence of SEQ ID NO: 267; and/or (c) the PD-1 axis binding antagonist is an anti-PD-L1 antibody.

In some ~~embodiment~~examples, the anti-CD3 antibody comprises an anti-CD20 arm comprising a N297G substitution mutation. In some ~~embodiment~~examples, the anti-CD3 antibody comprises an anti-CD3 arm comprising T366S, L368A, Y407V, and/or N297G substitution mutation(s) and an anti-CD20 arm comprising T366W and/or N297G substitution mutation(s). In some ~~embodiment~~examples, the anti-CD3 antibody comprises an anti-CD3 arm comprising a N297G substitution mutation. In some ~~embodiment~~examples, the anti-CD3 antibody comprises an anti-CD20 arm comprising T366S, L368A, Y407V, and/or N297G substitution mutation(s) and an anti-CD3 arm comprising T366W and/or N297G substitution mutation(s).

In some ~~embodiment~~examples, the anti-CD3 antibody comprises an anti-HER2 arm comprising a N297G substitution mutation. In some ~~embodiment~~examples, the anti-CD3 antibody comprises an anti-CD3 arm comprising T366S, L368A, Y407V, and/or N297G substitution mutation(s) and an anti-HER2 arm comprising N297G, N297A, L234A, L235A, and/or D265A substitution mutation(s). In some ~~embodiment~~examples, the anti-CD3 antibody comprises an anti-CD3 arm comprising a N297G substitution mutation. In some ~~embodiment~~examples, the anti-CD3 antibody comprises an anti-HER2 arm comprising T366S, L368A, Y407V, and/or N297G substitution mutation(s) and an anti-CD3 arm comprising N297G, N297A, L234A, L235A, and/or D265A substitution mutation(s).

In some ~~embodiment~~examples, the method further comprises administering to the subject a glucocorticoid. In some ~~embodiment~~examples, the glucocorticoid is selected from the group consisting of dexamethasone, hydrocortisone, cortisone, prednisolone, prednisone, methylprednisone, triamcinolone, paramethasone, betamethasone, fludrocortisone, and pharmaceutically acceptable esters, salts, and complexes thereof. In some ~~embodiment~~examples, the glucocorticoid is dexamethasone. In some ~~embodiment~~examples, the glucocorticoid is a pharmaceutically acceptable ester, salt, or complex of dexamethasone.

In some ~~embodiment~~examples, the method further comprises administering to the subject rituximab.

In some ~~embodiment~~examples, the method further comprises administering to the subject obinutuzumab.

In some ~~embodiment~~examples, the method further comprises administering to the subject an antibody-drug conjugate (ADC).

In any of the preceding uses or methods, the cell proliferative disorder can be cancer. In some ~~embodiment~~examples, the cancer is selected from the group consisting of breast cancer, colorectal cancer, non-small cell lung cancer, non-Hodgkin's lymphoma (NHL), B cell lymphoma, B cell leukemia, multiple myeloma, renal cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, glioblastoma, germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), Burkitt's lymphoma (BL), B-cell prolymphocytic leukemia, Splenic marginal zone lymphoma, Hairy cell leukemia, Splenic lymphoma/leukemia, unclassifiable, Splenic diffuse red pulp small B-cell lymphoma, Hairy cell leukemia variant, Waldenström macroglobulinemia, Heavy chain diseases, α Heavy chain disease, γ Heavy chain disease, μ Heavy chain disease, Plasma cell myeloma, Solitary plasmacytoma of bone, Extraosseous plasmacytoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Nodal marginal zone lymphoma, Pediatric nodal marginal zone lymphoma, Pediatric follicular lymphoma, Primary cutaneous follicle centre lymphoma, T-cell/histiocyte rich large B-cell lymphoma, Primary DLBCL of the CNS, Primary cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly, DLBCL associated with chronic inflammation, Lymphomatoid granulomatosis, Primary mediastinal (thymic) large B-cell lymphoma, Intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, Plasmablastic lymphoma, Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, Primary effusion lymphoma: B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma. In some ~~embodiment~~examples, the preferred cancer is germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), or Burkitt's lymphoma (BL)

In any of the preceding uses or methods, the autoimmune disorder can be selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE), Wegener's disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, multiple sclerosis, psoriasis, IgA nephropathy, IgM polyneuropathies, myasthenia gravis, vasculitis, diabetes mellitus, Reynaud's syndrome, Sjorgen's syndrome, glomerulonephritis, Neuromyelitis Optica (NMO) and IgG neuropathy.

In one aspect, the disclosure provides a kit comprising: (a) the composition as disclosed herein; and (b) a package insert comprising instructions for use of the composition to treat or delay progression of a cell proliferative disorder. In another ~~aspect~~example, the ~~invention~~disclosure features a kit comprising: (a) a composition comprising any one of the preceding anti-CD3 antibodies and (b) a package insert comprising instructions for administering the composition to a subject to treat or delay progression of a cell proliferative disorder.

In any of the preceding uses or methods, the subject can be a human.

WHAT IS CLAIMED IS:

1. An anti-cluster of differentiation 3 (CD3) antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six hypervariable regions (HVRs):

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 4;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

2. The anti-CD3 antibody of claim 1, wherein the binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 184; (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 185; or (c) a VH domain as in (a) and a VL domain as in (b).

3. The anti-CD3 antibody of claim 2, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 184.

4. The anti-CD3 antibody of claim 2, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 185.

5. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185.

6. The anti-CD3 antibody of claim 1, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 186; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 187; or (c) a VH domain as in (a) and a VL domain as in (b).

7. The anti-CD3 antibody of claim 6, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 186.

8. The anti-CD3 antibody of claim 6, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 187.

9. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 186 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 187.

10. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;

(c) an HVR-H3 comprising the amino acid sequence of $X_1X_2YSX_3X_4X_5FDY$, wherein X_1 is selected from the group consisting of D, T, and S; X_2 is selected from the group consisting of G, A, and S; X_3 is R or N; X_4 is Y or A; and X_5 is Y or A (SEQ ID NO: 181);

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and

(f) an HVR-L3 comprising the amino acid sequence of $X_1X_2SX_3X_4LRT$, wherein X_1 is K or T; X_2 is Q or A; X_3 is F or A; and X_4 is I or A (SEQ ID NO: 182).

11. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12.

12. The anti-CD3 antibody of claim 11, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 188; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 189; or (c) a VH domain as in (a) and a VL domain as in (b).

13. The anti-CD3 antibody of claim 12, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 188.

14. The anti-CD3 antibody of claim 12, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 189.

15. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 188 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 189.

16. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 13;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12.

17. The anti-CD3 antibody of claim 16, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 190; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 191; or (c) a VH domain as in (a) and a VL domain as in (b).

18. The anti-CD3 antibody of claim 17, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 190.

19. The anti-CD3 antibody of claim 17, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 191.

20. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 190 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 191.

21. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 14.

22. The anti-CD3 antibody of claim 21, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 192; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 193; or (c) a VH domain as in (a) and a VL domain as in (b).

23. The anti-CD3 antibody of claim 22, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 192.

24. The anti-CD3 antibody of claim 22, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 193.

25. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 192 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 193.

26. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 15.

27. The anti-CD3 antibody of claim 26, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 194; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 195; or (c) a VH domain as in (a) and a VL domain as in (b).

28. The anti-CD3 antibody of claim 27, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 194.

29. The anti-CD3 antibody of claim 27, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 195.

30. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 194 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 195.

31. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 16.

32. The anti-CD3 antibody of claim 31, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 196; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 197; or (c) a VH domain as in (a) and a VL domain as in (b).

33. The anti-CD3 antibody of claim 32, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 196.

34. The anti-CD3 antibody of claim 32, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 197.

35. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 196 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 197.

36. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 17;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12.

37. The anti-CD3 antibody of claim 36, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 198; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 199; or (c) a VH domain as in (a) and a VL domain as in (b).

38. The anti-CD3 antibody of claim 37, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 198.

39. The anti-CD3 antibody of claim 37, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 199.

40. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 198 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 199.

41. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 18;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12.

42. The anti-CD3 antibody of claim 41, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 200; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 201; or (c) a VH domain as in (a) and a VL domain as in (b).

43. The anti-CD3 antibody of claim 42, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 200.

44. The anti-CD3 antibody of claim 42, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 201.

45. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 200 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 201.

46. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 19;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12.

47. The anti-CD3 antibody of claim 46, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 202; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 203; or (c) a VH domain as in (a) and a VL domain as in (b).

48. The anti-CD3 antibody of claim 47, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 202.

49. The anti-CD3 antibody of claim 47, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 203.

50. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 202 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 203.

51. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 20;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12.

52. The anti-CD3 antibody of claim 51, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 204; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 205; or (c) a VH domain as in (a) and a VL domain as in (b).

53. The anti-CD3 antibody of claim 52, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 204.

54. The anti-CD3 antibody of claim 52, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 205.

55. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 204 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 205.

56. The anti-CD3 antibody of claim 10, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 21;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 22.

57. The anti-CD3 antibody of claim 56, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 206; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 207; or (c) a VH domain as in (a) and a VL domain as in (b).

58. The anti-CD3 antibody of claim 57, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 206.

59. The anti-CD3 antibody of claim 57, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 207.

60. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 206 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 207.

61. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23;

(b) an HVR-H2 comprising the amino acid sequence of LINPYKGVX$_1$TYX$_2$X$_3$X$_4$X$_5$KX$_6$, wherein X$_1$ is S or T; X$_2$ is N or A; X$_3$ is Q or D; X$_4$ is K or S; X$_5$ is F or V; and X$_6$ is D or G (SEQ ID NO: 183);

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28.

62. The anti-CD3 antibody of claim 61, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 24;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28.

63. The anti-CD3 antibody of claim 62, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 208; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 209; or (c) a VH domain as in (a) and a VL domain as in (b).

64. The anti-CD3 antibody of claim 63, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 208.

65. The anti-CD3 antibody of claim 63, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 209.

66. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 208 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 209.

67. The anti-CD3 antibody of claim 61, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 29;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28.

68. The anti-CD3 antibody of claim 67, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 210; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 211; or (c) a VH domain as in (a) and a VL domain as in (b).

69. The anti-CD3 antibody of claim 68, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 210.

70. The anti-CD3 antibody of claim 68, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 211.

71. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 210 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 211.

72. The anti-CD3 antibody of claim 61, wherein the binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 30;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28.

73. The anti-CD3 antibody of claim 72, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 212; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 213; or (c) a VH domain as in (a) and a VL domain as in (b).

74. The anti-CD3 antibody of claim 73, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 212.

75. The anti-CD3 antibody of claim 73, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 213.

76. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 212 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 213.

77. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 31;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 32;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 33;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 34;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 35; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 36.

78. The anti-CD3 antibody of claim 77, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 214; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 215; or (c) a VH domain as in (a) and a VL domain as in (b).

79. The anti-CD3 antibody of claim 78, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 214.

80. The anti-CD3 antibody of claim 78, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 215.

81. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 214 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 215.

82. The anti-CD3 antibody of claim 77, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 216; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 217; or (c) a VH domain as in (a) and a VL domain as in (b).

83. The anti-CD3 antibody of claim 82, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 216.

84. The anti-CD3 antibody of claim 82, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 217.

85. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 216 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 217.

86. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 37;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 38;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 40;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 41; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 42.

87. The anti-CD3 antibody of claim 86, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 218; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 219; or (c) a VH domain as in (a) and a VL domain as in (b).

88. The anti-CD3 antibody of claim 87, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 218.

89. The anti-CD3 antibody of claim 87, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 219.

90. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 218 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 219.

91. The anti-CD3 antibody of claim 86, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 220; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 221; or (c) a VH domain as in (a) and a VL domain as in (b).

92. The anti-CD3 antibody of claim 91, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 220.

93. The anti-CD3 antibody of claim 91, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 221.

94. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 220 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 221.

95. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 43;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 44;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 45;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 46;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 47; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 48.

96. The anti-CD3 antibody of claim 95, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 222; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 223; or (c) a VH domain as in (a) and a VL domain as in (b).

97. The anti-CD3 antibody of claim 96, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 222.

98. The anti-CD3 antibody of claim 96, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 223.

99. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 222 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 223.

100. The anti-CD3 antibody of claim 95, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 224; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 225; or (c) a VH domain as in (a) and a VL domain as in (b).

101. The anti-CD3 antibody of claim 100, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 224.

102. The anti-CD3 antibody of claim 100, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 225.

103. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 224 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 225.

104. The anti-CD3 antibody of claim 95, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of

~~SEQ ID NO: 226; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 227; or (c) a VH domain as in (a) and a VL domain as in (b).~~

~~105. The anti-CD3 antibody of claim 104, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 226.~~

~~106. The anti-CD3 antibody of claim 104, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 227.~~

~~107. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 226 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 227.~~

~~108. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:~~

~~(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 49;~~
~~(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 50;~~
~~(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 51;~~
~~(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 52;~~
~~(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and~~
~~(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 54.~~

~~109. The anti-CD3 antibody of claim 108, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 228; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 229; or (c) a VH domain as in (a) and a VL domain as in (b).~~

~~110. The anti-CD3 antibody of claim 109, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 228.~~

~~111. The anti-CD3 antibody of claim 109, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 229.~~

~~112. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 228 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 229.~~

113. The anti-CD3 antibody of claim 108, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 230; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 231; or (c) a VH domain as in (a) and a VL domain as in (b).

114. The anti-CD3 antibody of claim 113, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 230.

115. The anti-CD3 antibody of claim 113, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 231.

116. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 230 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 231.

117. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 55;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 56;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 57;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 58;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 59; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 60.

118. The anti-CD3 antibody of claim 117, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 232; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 233; or (c) a VH domain as in (a) and a VL domain as in (b).

119. The anti-CD3 antibody of claim 118, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 232.

120. The anti-CD3 antibody of claim 118, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 233.

121. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 232 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 233.

122. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 61;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 62;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 63;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 64;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 65; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 66.

123. The anti-CD3 antibody of claim 122, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 234; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 235; or (c) a VH domain as in (a) and a VL domain as in (b).

124. The anti-CD3 antibody of claim 123, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 234.

125. The anti-CD3 antibody of claim 123, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 235.

126. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 234 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 235.

127. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 67;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 68;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 69;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 70;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 71; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 72.

128. The anti-CD3 antibody of claim 127, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 236; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 237; or (c) a VH domain as in (a) and a VL domain as in (b).

~~129. The anti-CD3 antibody of claim 128, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 236.~~

~~130. The anti-CD3 antibody of claim 128, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 237.~~

~~131. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 236 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 237.~~

~~132. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:~~

~~(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 73;~~

~~(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 74;~~

~~(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 75;~~

~~(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 76;~~

~~(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 77; and~~

~~(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 78.~~

~~133. The anti-CD3 antibody of claim 132, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 238; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 239; or (c) a VH domain as in (a) and a VL domain as in (b).~~

~~134. The anti-CD3 antibody of claim 133, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 238.~~

~~135. The anti-CD3 antibody of claim 133, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 239.~~

~~136. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 238 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 239.~~

~~137. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:~~

~~(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 79;~~

~~(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 80;~~

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 81;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 82;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 83; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 84.

138. The anti-CD3 antibody of claim 137, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 240; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 241; or (c) a VH domain as in (a) and a VL domain as in (b).

139. The anti-CD3 antibody of claim 138, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 240.

140. The anti-CD3 antibody of claim 138, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 241.

141. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 240 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 241.

142. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 85;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 86;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 87;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 88;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 89; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 90.

143. The anti-CD3 antibody of claim 142, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 242; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 243; or (c) a VH domain as in (a) and a VL domain as in (b).

144. The anti-CD3 antibody of claim 143, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 242.

145. The anti-CD3 antibody of claim 143, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 243.

146. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 242 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 243.

147. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 91;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 92;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 93;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 94;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 95; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 96.

148. The anti-CD3 antibody of claim 147, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 244; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 245; or (c) a VH domain as in (a) and a VL domain as in (b).

149. The anti-CD3 antibody of claim 148, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 244.

150. The anti-CD3 antibody of claim 148, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 245.

151. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 244 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 245.

152. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 97;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 98;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 99;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 100;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 101; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 102.

153. The anti-CD3 antibody of claim 152, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 246; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 247; or (c) a VH domain as in (a) and a VL domain as in (b).

154. The anti-CD3 antibody of claim 153, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 246.

155. The anti-CD3 antibody of claim 153, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 247.

156. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 246 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 247.

157. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 103;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 104;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 105;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 106;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 107; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 108.

158. The anti-CD3 antibody of claim 157, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 248; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 249; or (c) a VH domain as in (a) and a VL domain as in (b).

159. The anti-CD3 antibody of claim 158, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 248.

160. The anti-CD3 antibody of claim 158, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 249.

161. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 248 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 249.

162. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 109;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 110;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 111;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 112;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 113; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 114.

163. The anti-CD3 antibody of claim 162, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 250; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 251; or (c) a VH domain as in (a) and a VL domain as in (b).

164. The anti-CD3 antibody of claim 163, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 250.

165. The anti-CD3 antibody of claim 163, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 251.

166. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 250 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 251.

167. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 117;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 120.

168. The anti-CD3 antibody of claim 167, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of

SEQ ID NO: 252; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 253; or (c) a VH domain as in (a) and a VL domain as in (b).

169. The anti-CD3 antibody of claim 168, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 252.

170. The anti-CD3 antibody of claim 168, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 253.

171. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 252 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 253.

172. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 121;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 122;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 123;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 124;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 125; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 126.

173. The anti-CD3 antibody of claim 172, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 254; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 255; or (c) a VH domain as in (a) and a VL domain as in (b).

174. The anti-CD3 antibody of claim 173, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 254.

175. The anti-CD3 antibody of claim 173, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 255.

176. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 254 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 255.

177. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 127;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 128;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 129;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 130;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 131; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 132.

178. The anti-CD3 antibody of claim 177, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 256; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 257; or (c) a VH domain as in (a) and a VL domain as in (b).

179. The anti-CD3 antibody of claim 178, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 256.

180. The anti-CD3 antibody of claim 178, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 257.

181. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 256 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 257.

182. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 133;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 134;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 135;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 136;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 137; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 138.

183. The anti-CD3 antibody of claim 182, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 258; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 259; or (c) a VH domain as in (a) and a VL domain as in (b).

184. The anti-CD3 antibody of claim 183, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 258.

185. The anti-CD3 antibody of claim 183, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 259.

186. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 258 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 259.

187. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 139;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 140;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 141;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 142;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 143; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 144.

188. The anti-CD3 antibody of claim 187, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 260; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 261; or (c) a VH domain as in (a) and a VL domain as in (b).

189. The anti-CD3 antibody of claim 188, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 260.

190. The anti-CD3 antibody of claim 188, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 261.

191. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 260 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 261.

192. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 145;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 146;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 147;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 148;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 149; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 150.

193. The anti-CD3 antibody of claim 192, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 262; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 263; or (c) a VH domain as in (a) and a VL domain as in (b).

194. The anti-CD3 antibody of claim 193, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 262.

195. The anti-CD3 antibody of claim 193, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 263.

196. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 262 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 263.

197. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 151;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 152;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 153;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 154;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 155; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 156.

198. The anti-CD3 antibody of claim 197, wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 264; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 265; or (c) a VH domain as in (a) and a VL domain as in (b).

199. The anti-CD3 antibody of claim 198, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 264.

200. The anti-CD3 antibody of claim 198, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 265.

201. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 264 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 265.

202. An anti-CD3 antibody, wherein the anti-CD3 antibody binds to an epitope on CD3 comprising amino acid residue Glu6 of CD3.

203. The anti-CD3 antibody of claim 202, wherein the epitope further comprises one or more additional amino acid residues selected from the group consisting of Gln1, Asp2, and Met7 of CD3.

204. The anti-CD3 antibody of claim 202 or 203, wherein the epitope comprises amino acid residues Gln1, Asp2, and Glu6 of CD3.

205. The anti-CD3 antibody of any one of claims 202-204, wherein the epitope comprises amino acid residues Gln1, Asp2, Glu6, and Met7 of CD3.

206. The anti-CD3 antibody of any one of claims 202-205, wherein the epitope does not comprise amino acid residue Glu5 of CD3.

207. The anti-CD3 antibody of any one of claims 202-206, wherein the epitope does not comprise amino acid residues Gly3 and Glu5 of CD3.

208. The anti-CD3 antibody of any one of claims 202-207, wherein the epitope consists of amino acid residues Gln1, Asp2, Glu6, and Met7 of CD3.

209. The anti-CD3 antibody of any one of claims 1-208, wherein the binding domain binds to a human CD3 polypeptide or a cynomolgus monkey (cyno) CD3 polypeptide.

210. The anti-CD3 antibody of claim 209, wherein the human CD3 polypeptide or the cyno CD3 polypeptide is a human CD3ε polypeptide or a cyno CD3ε polypeptide, respectively.

211. The anti-CD3 antibody of claim 210, wherein the human CD3 polypeptide or the cyno CD3 polypeptide is a human CD3γ polypeptide or a cyno CD3γ polypeptide, respectively.

212. The anti-CD3 antibody of any one of claims 1-211, wherein the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 250 nM or lower.

213. The anti-CD3 antibody of claim 2122, wherein the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 100 nM or lower.

214. The anti-CD3 antibody of claim 213, wherein the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 15 nM or lower.

215. The anti-CD3 antibody of claim 214, wherein the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 10 nM or lower.

216. The anti-CD3 antibody of claim 215, wherein the anti-CD3 antibody binds the human CD3ε polypeptide with a Kd of 5 nM or lower.

217. The anti-CD3 antibody of any one of claims 1-216, wherein the anti-CD3 antibody comprises an aglycosylation site mutation.

218. The anti-CD3 antibody of claim 217, wherein the aglycosylation site mutation is a substitution mutation.

219. The anti-CD3 antibody of claim 217 or 218, wherein the aglycosylation site mutation reduces effector function of the anti-CD3 antibody.

220. The anti-CD3 antibody of any one of claims 1-218, wherein the anti-CD3 antibody comprises a substitution mutation in the Fc region that reduces effector function.

221. The anti-CD3 antibody of claim 218 or 220, wherein the substitution mutation is at amino acid residue N297, L234, L235, and/or D265 (EU numbering).

222. The anti-CD3 antibody of claim 221, wherein the substitution mutation is selected from the group consisting of N297G, N297A, L234A, L235A, and D265A.

223. The anti-CD3 antibody of claim 222, wherein the substitution mutation is an N297G mutation.

224. The anti-CD3 antibody of any one of claims 1-223, wherein the anti-CD3 antibody is monoclonal, human, humanized, or chimeric.

225. The anti-CD3 antibody of any one of claims 1-224, wherein the anti-CD3 antibody is an antibody fragment that binds CD3.

226. The anti-CD3 antibody of claim 225, wherein the antibody fragment is selected from the group consisting of Fab, Fab'-SH, Fv, scFv, and $(Fab')_2$ fragments.

227. The anti-CD3 antibody of any one of claims 1-224, wherein the anti-CD3 antibody is a full-length antibody.

228. The anti-CD3 antibody of any one of claims 1-227, wherein the anti-CD3 antibody is an IgG antibody.

229. The anti-CD3 antibody of any one of claims 1-228, wherein the anti-CD3 antibody is a monospecific antibody.

230. The anti-CD3 antibody of any one of claims 1-228, wherein the anti-CD3 antibody is a multispecific antibody.

231. The anti-CD3 antibody of claim 230, wherein the multispecific antibody is a bispecific antibody.

232. The anti-CD3 antibody of claim 231, wherein the bispecific antibody comprises a second binding domain that binds to a second biological molecule, wherein the second biological molecule is a cell surface antigen.

233. The anti-CD3 antibody of claim 232, wherein the cell surface antigen is a tumor antigen.

234. The anti-CD3 antibody of claim 233, wherein the tumor antigen is selected from the group consisting of CD20, HER2, FcRH5 (Fc Receptor-like 5), and LYPD1.

235. The anti-CD3 antibody of claim 234, wherein the tumor antigen is selected from the group consisting of CD20 and HER2.

236. The anti-CD3 antibody of claim 234, wherein the tumor antigen is CD20 and the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 157;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 158;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 159;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 160;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 161; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 162.

237. The anti-CD3 antibody of claim 235, wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 266; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 267; or (c) a VH domain as in (a) and a VL domain as in (b).

238. The anti-CD3 antibody of claim 237, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 266.

239. The anti-CD3 antibody of claim 237, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 267.

240. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267.

241. The anti-CD3 antibody of claim 234, wherein the tumor antigen is FcRH5 and the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 163;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 164;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 165;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 166;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 167; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 168.

242. The anti-CD3 antibody of claim 241, wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 268; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 269; or (c) a VH domain as in (a) and a VL domain as in (b).

243. The anti-CD3 antibody of claim 242, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 268.

244. The anti-CD3 antibody of claim 242, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 269.

245. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 268 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 269.

246. The anti-CD3 antibody of claim 234, wherein the tumor antigen is HER2 and the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 169;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 170;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 171;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 172;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 173; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 174.

247. The anti-CD3 antibody of claim 246, wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 270; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 271; or (c) a VH domain as in (a) and a VL domain as in (b).

248. The anti-CD3 antibody of claim 247, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 270.

249. The anti-CD3 antibody of claim 247, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 271.

250. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 270 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 271.

251. The anti-CD3 antibody of claim 234, wherein the tumor antigen is HER2 and the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 581;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 582;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 583;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 584;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 585; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 586.

252. The anti-CD3 antibody of claim 251, wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 593; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 594; or (c) a VH domain as in (a) and a VL domain as in (b).

253. The anti-CD3 antibody of claim 252, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 593.

254. The anti-CD3 antibody of claim 252, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 594.

255. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 593 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 594.

256. The anti-CD3 antibody of claim 234, wherein the tumor antigen is HER2 and the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 587;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 588;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 589;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 590;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 591; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 592.

257. The anti-CD3 antibody of claim 256, wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 595; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 596; or (c) a VH domain as in (a) and a VL domain as in (b).

258. The anti-CD3 antibody of claim 257, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 595.

259. The anti-CD3 antibody of claim 257, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 596.

260. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 595 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 596.

261. The anti-CD3 antibody of claim 234, wherein the tumor antigen is LYPD1 and the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 175;

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 176;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 177;

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 178;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 179; and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 180.

262. The anti-CD3 antibody of claim 261, wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid

sequence of SEQ ID NO: 272; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 273; or (c) a VH domain as in (a) and a VL domain as in (b).

263. The anti-CD3 antibody of claim 262, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 272.

264. The anti-CD3 antibody of claim 262, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 273.

265. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 272 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 273.

266. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 4;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and

an anti-CD20 arm comprising a second binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 157;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 158;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:159;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 160;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 161; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 162.

267. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185, and an anti-CD20 arm comprising a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267.

268. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185, and an anti-CD20 arm comprising a second binding domain comprising (a) a VH domain comprising an amino acid sequence of

SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267, wherein the anti-CD3 antibody comprises an N297G substitution mutation.

269. An anti-CD3 antibody, wherein the anti-CD3 antibody comprises an anti-CD3 arm comprising a first binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 185, and an anti-CD20 arm comprising a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 267, wherein (a) the anti-CD3 arm comprises T366S, L368A, Y407V, and N297G substitution mutations and (b) the anti-CD20 arm comprises T366W and N297G substitution mutations.

270. The anti-CD3 antibody of any one of claims 1-269, wherein the anti-CD3 antibody comprises one or more heavy chain constant domains, wherein the one or more heavy chain constant domains are selected from a first CH1 ($CH1_1$) domain, a first CH2 ($CH2_1$) domain, a first CH3 ($CH3_1$) domain, a second CH1 ($CH1_2$) domain, second CH2 ($CH2_2$) domain, and a second CH3 ($CH3_2$) domain.

271. The anti-CD3 antibody of claim 270, wherein at least one of the one or more heavy chain constant domains is paired with another heavy chain constant domain.

272. The anti-CD3 antibody of claim 271, wherein the $CH3_1$ and $CH3_2$ domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the $CH3_1$ domain is positionable in the cavity or protuberance, respectively, in the $CH3_2$ domain.

273. The anti-CD3 antibody of claim 272, wherein the $CH3_1$ and $CH3_2$ domains meet at an interface between said protuberance and cavity.

274. The anti-CD3 antibody of any one of claims 270-273, wherein the $CH2_1$ and $CH2_2$ domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the $CH2_1$ domain is positionable in the cavity or protuberance, respectively, in the $CH2_2$ domain.

275. The anti-CD3 antibody of claim 274, wherein the $CH2_1$ and $CH2_2$ domains meet at an interface between said protuberance and cavity.

276. The anti-CD3 antibody of any one of claims 1-275, wherein the half-life of the anti-CD3 antibody is about 7 days.

277. An isolated nucleic acid encoding the anti-CD3 antibody of any one of claims 1-276.

278. A vector comprising the isolated nucleic acid of claim 277.

279. A host cell comprising the vector of claim 278.

280. The host cell of claim 279, wherein the host cell is a mammalian cell.

281. The host cell of claim 280, wherein the mammalian cell is a Chinese hamster ovary (CHO) cell.

282. The host cell of claim 281, wherein the host cell is a prokaryotic cell.

283. The host cell of claim 282, wherein the prokaryotic cell is *E. coli*.

284. A method of producing the anti-CD3 antibody of any one of claims 1-276, the method comprising culturing the host cell of claim 279 in a culture medium.

285. The method of claim 284, wherein the method further comprises recovering the anti-CD3 antibody from the host cell or the culture medium.

286. An immunoconjugate comprising the anti-CD3 antibody of any one of claims 1-276 and a cytotoxic agent.

287. A composition comprising the anti-CD3 antibody of any one of claims 1-276.

288. The composition of claim 287, further comprising a pharmaceutically acceptable carrier, excipient, or diluent.

289. The composition of claim 288, wherein the composition is a pharmaceutical composition.

290. The composition of any one of claims 287-289, wherein the composition further comprises a PD-1 axis binding antagonist or an additional therapeutic agent.

291. The anti-CD3 antibody of any one of claims 1-276 for use as a medicament.

292. The anti-CD3 antibody of any one of claims 1-276 for use in treating or delaying progression of a cell proliferative disorder or an autoimmune disorder in a subject in need thereof.

293. The anti-CD3 antibody of any one of claims 1-276 for use in enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder.

294. The anti-CD3 antibody of claim 292 or claim 293, wherein the cell proliferative disorder is a cancer.

295. The anti-CD3 antibody of claim 294, wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, non-small cell lung cancer, non-Hodgkin's lymphoma (NHL), B-cell lymphoma, B-cell leukemia, multiple myeloma, renal cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, glioblastoma, germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), Burkitt's lymphoma (BL), B-cell prolymphocytic leukemia, Splenic marginal zone lymphoma, Hairy cell leukemia, Splenic lymphoma/leukemia, unclassifiable, Splenic diffuse red pulp small B-cell lymphoma, Hairy cell leukemia variant, Waldenström macroglobulinemia, Heavy chain diseases, α Heavy chain disease, γ Heavy chain disease, μ Heavy chain disease, Plasma cell myeloma, Solitary plasmacytoma of bone, Extraosseous plasmacytoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Nodal marginal zone lymphoma, Pediatric nodal marginal zone lymphoma, Pediatric follicular lymphoma, Primary cutaneous follicle centre lymphoma, T-cell/histiocyte rich large B-cell lymphoma, Primary DLBCL of the CNS, Primary cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly, DLBCL associated with chronic inflammation, Lymphomatoid granulomatosis, Primary mediastinal (thymic) large B-cell lymphoma, Intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, Plasmablastic lymphoma, Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, Primary effusion lymphoma: B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma.

296. The anti-CD3 antibody of claim 295, wherein the cancer is germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), or Burkitt's lymphoma (BL).

297. The anti-CD3 antibody of claim 292 or claim 293, wherein the autoimmune disorder is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE), Wegener's disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, multiple sclerosis, psoriasis, IgA nephropathy, IgM polyneuropathies, myasthenia gravis, vasculitis, diabetes mellitus, Reynaud's syndrome, Sjorgen's syndrome, glomerulonephritis, Neuromyelitis Optica (NMO) and IgG neuropathy.

298. Use of the anti-CD3 antibody of any one of claims 1-276 in the manufacture of a medicament for treating or delaying progression of a cell proliferative disorder or an autoimmune disorder.

299. Use of the anti-CD3 antibody of any one of claims 1-276 in the manufacture of a medicament for enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder.

300. The use of claim 298 or claim 299, wherein the cell proliferative disorder is a cancer.

301. The use of claim 300, wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, non-small cell lung cancer, non-Hodgkin's lymphoma (NHL), B-cell lymphoma, B-cell leukemia, multiple myeloma, renal cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, glioblastoma, germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), Burkitt's lymphoma (BL), B-cell prolymphocytic leukemia, Splenic marginal zone lymphoma, Hairy cell leukemia, Splenic lymphoma/leukemia, unclassifiable, Splenic diffuse red pulp small B-cell lymphoma, Hairy cell leukemia variant, Waldenström macroglobulinemia, Heavy chain diseases, α Heavy chain disease, γ Heavy chain disease, μ Heavy chain disease, Plasma cell myeloma, Solitary plasmacytoma of bone, Extraosseous plasmacytoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Nodal marginal zone lymphoma, Pediatric nodal marginal zone lymphoma, Pediatric follicular lymphoma, Primary cutaneous follicle centre lymphoma, T-cell/histiocyte rich large B-cell lymphoma, Primary DLBCL of the CNS, Primary cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly, DLBCL associated with chronic inflammation, Lymphomatoid granulomatosis, Primary mediastinal (thymic) large B-cell lymphoma, Intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, Plasmablastic lymphoma, Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, Primary effusion lymphoma: B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma.

302. The use of claim 301, wherein the cancer is germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), or Burkitt's lymphoma (BL).

303. The use of claim 298 or claim 299, wherein the autoimmune disorder is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE), Wegener's disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, multiple sclerosis, psoriasis, IgA nephropathy, IgM polyneuropathies, myasthenia gravis, vasculitis, diabetes mellitus, Reynaud's syndrome, Sjorgen's syndrome, glomerulonephritis, Neuromyelitis Optica (NMO) and IgG neuropathy.

304. A method of treating or delaying the progression of a cell proliferative disorder or an autoimmune disorder in a subject in need thereof, the method comprising administering to the subject the anti-CD3 antibody of any one of claims 1-276.

305. A method of enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder, the method comprising administering to the subject an effective amount of the anti-CD3 antibody of any one of claims 1-276.

306. The method of claim 304 or claim 305, wherein the cell proliferative disorder is a cancer.

307. The method of claim 306, wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, non-small cell lung cancer, non-Hodgkin's lymphoma (NHL), B cell lymphoma, B cell leukemia, multiple myeloma, renal cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, glioblastoma, germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), Burkitt's lymphoma (BL), B-cell prolymphocytic leukemia, Splenic marginal zone lymphoma, Hairy cell leukemia, Splenic lymphoma/leukemia, unclassifiable, Splenic diffuse red pulp small B-cell lymphoma, Hairy cell leukemia variant, Waldenström macroglobulinemia, Heavy chain diseases, α Heavy chain disease, γ Heavy chain disease, μ Heavy chain disease, Plasma cell myeloma, Solitary plasmacytoma of bone, Extraosseous plasmacytoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Nodal marginal zone lymphoma, Pediatric nodal marginal zone lymphoma, Pediatric follicular lymphoma, Primary cutaneous follicle centre lymphoma, T-cell/histiocyte rich large B-cell lymphoma, Primary DLBCL of the CNS, Primary cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly, DLBCL associated with chronic inflammation, Lymphomatoid granulomatosis, Primary mediastinal (thymic) large B-cell lymphoma, Intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, Plasmablastic lymphoma, Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, Primary effusion lymphoma: B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma.

308. The method of claim 307, wherein the cancer is germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), or Burkitt's lymphoma (BL).

309. The method of claim 304 or claim 305, wherein the autoimmune disorder is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE), Wegener's disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, multiple sclerosis, psoriasis, IgA nephropathy, IgM polyneuropathies, myasthenia gravis, vasculitis, diabetes mellitus, Reynaud's syndrome, Sjorgen's syndrome, glomerulonephritis, Neuromyelitis Optica (NMO) and IgG neuropathy.

310. The method of any one of claims 304-309, wherein the anti-CD3 antibody binds to (a) a CD3 molecule located on an immune effector cell and (b) a second biological molecule located on a target cell other than the immune effector cell.

311. The method of claim 310, wherein the anti-CD3 antibody activates the immune effector cell following binding to (a) and (b).

312. The method of claim 311, wherein the activated immune effector cell is capable of exerting a cytotoxic effect and/or an apoptotic effect on the target cell.

313. The method of any one of claims 304-312, wherein the anti-CD3 antibody is administered to the subject in a dosage of about 0.01 mg/kg to about 10 mg/kg.

314. The method of claim 313, wherein the anti-CD3 antibody is administered to the subject in a dosage of about 0.1 mg/kg to about 10 mg/kg.

315. The method of claim 314, wherein the anti-CD3 antibody is administered to the subject in a dosage of about 1 mg/kg.

316. The method of any one of claims 304-315, further comprising administering to the subject a PD-1 axis binding antagonist and/or an additional therapeutic agent.

317. The method of claim 316, wherein the PD-1 axis binding antagonist or additional therapeutic agent is administered prior to or subsequent to the administration of the anti-CD3 antibody.

318. The method of claim 317, wherein the PD-1 axis binding antagonist additional therapeutic agent is administered concurrently with the anti-CD3 antibody.

319. The method of any one of claims 316-318, wherein the PD-1 axis binding antagonist is selected from the group consisting of a PD-1 binding antagonist, a PD-L1 binding antagonist, and a PD-L2 binding antagonist.

320. The method of claim 319, wherein the PD-1 axis binding antagonist is a PD-1 binding antagonist.

321. The method of claim 320, wherein the PD-1 binding antagonist is selected from the group consisting of MDX-1106 (nivolumab), MK-3475 (lambrolizumab), CT-011 (pidilizumab), and AMP-224.

322. The method of claim 319, wherein the PD-1 axis binding antagonist is a PD-L1 binding antagonist.

323. The method of claim 322, wherein the PD-L1 binding antagonist is selected from the group consisting of: YW243.55.S70, MPDL3280A, MDX-1105, and MEDI4736.

324. The method of claim 319, wherein the PD-1 axis binding antagonist is a PD-L2 binding antagonist.

325. The method of claim 324, wherein the PD-L2 binding antagonist is an antibody or an immunoadhesin.

326. A method of treating or delaying the progression of a cell proliferative disorder or an autoimmune disorder in a subject in need thereof, the method comprising administering to the subject an anti-CD3 antibody and a PD-1 axis binding antagonist, wherein the anti-CD3 antibody comprises an anti-CD3 arm and an anti-CD20 arm.

327. A method of enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder, the method comprising administering to the subject an anti-CD3 antibody and a PD-1 axis binding antagonist, wherein the anti-CD3 antibody comprises an anti-CD3 arm and an anti-CD20 arm.

328. The method of claim 326 or 327, wherein:

(a) the anti-CD3 arm comprises a first binding domain comprising:

(i) a VH domain comprising an amino acid sequence of SEQ ID NO: 184, and

(ii) a VL domain comprising an amino acid sequence of SEQ ID NO: 185; and

(b) the anti-CD20 arm comprises a second binding domain comprising:

(i) a VH domain comprising an amino acid sequence of SEQ ID NO: 266, and

(ii) a VL domain comprising an amino acid sequence of SEQ ID NO: 267; and

(c) the PD-1 axis binding antagonist is an anti-PD-L1 antibody.

329. The method of any one of claims 304-328, further comprising administering to the subject a glucocorticoid.

330. The method of claim 329, wherein the glucocorticoid is dexamethasone.

331. The method of any one of claims 304-330, further comprising administering to the subject rituximab.

~~332. The method of any one of claims 304-330, further comprising administering to the subject obinutuzumab.~~

~~333. The method of any one of claims 304-332, further comprising administering to the subject an antibody-drug conjugate (ADC).~~

~~334. The method of any one of claims 304-333, wherein the anti-CD3 antibody is administered subcutaneously, intravenously, intramuscularly, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally.~~

~~335. The method of claim 334, wherein the anti-CD3 antibody is administered subcutaneously.~~

~~336. The method of claim 335, wherein the anti-CD3 antibody is administered intravenously.~~

~~337. The method of any one of claims 304-336, wherein the subject is a human.~~

~~338. A kit comprising:~~

~~(a) the composition of any one of claims 287-290; and~~

~~(b) a package insert comprising instructions for administering the composition to a subject to treat or delay progression of a cell proliferative disorder or an autoimmune disorder.~~

1. An anti-CD3 antibody which is a bispecific antibody, wherein the bispecific antibody comprises:

an anti-CD3 arm comprising a first binding domain comprising the following six hypervariable regions (HVRs):

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 7,

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8,

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9,

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 10,

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11, and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12; and

an anti-LYPD1 arm comprising a second binding domain comprising the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 175,

(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 176,

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 177,

(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 178,

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 179, and

(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 180.

2. The bispecific antibody of claim 1, wherein the first binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the

amino acid sequence of SEQ ID NO: 188; (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 189; or (c) a VH domain as in (a) and a VL domain as in (b).

3. The bispecific antibody of claim 2, wherein the VH domain of the first binding domain comprises the amino acid sequence of SEQ ID NO: 188 and/or the VL domain comprises the amino acid sequence of SEQ ID NO: 189.

4. The bispecific antibody of any one of claims 1-3, wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 272; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 273; or (c) a VH domain as in (a) and a VL domain as in (b).

5. The bispecific antibody of claim 4, wherein the VH domain of the second binding domain comprises an amino acid sequence of SEQ ID NO: 272 and/or the VL domain comprising an amino acid sequence of SEQ ID NO: 273.

6. The bispecific antibody of any one of claims 1-3, wherein the anti-CD3 arm comprises a first binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 188 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 189, and the anti-LYPD1 arm comprises a second binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 272 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 273.

7. The bispecific antibody of any one of claims 1-6, wherein the first binding domain binds to a human CD3 polypeptide or a cynomolgus monkey (cyno) CD3 polypeptide.

8. The bispecific antibody of claim 7, wherein (a) the human CD3 polypeptide is a human CD3ε polypeptide or a human CD3γ polypeptide; or (b) the cyno CD3 polypeptide is a cyno CD3ε polypeptide or a cyno CD3γ polypeptide.

9. The bispecific antibody of any one of claims 1-8, wherein the bispecific antibody comprises an aglycosylation site mutation.

10. The bispecific antibody of claim 9, wherein the aglycosylation site mutation reduces effector function of the bispecific antibody.

11. The bispecific antibody of claim 9 or 10, wherein the aglycosylation site mutation is a substitution mutation.

12. The bispecific antibody of any one of claims 1-10, wherein the bispecific antibody comprises a substitution mutation in the Fc region that reduces effector function.

13. The bispecific antibody of claim 11 or 12, wherein the substitution mutation is at amino acid residue N297, L234, L235, and/or D265 (EU numbering).

14. The bispecific antibody of claim 13, wherein the substitution mutation is selected from the group consisting of N297G, N297A, L234A, L235A, and D265A.

15. The bispecific antibody of any one of claims 1-14, wherein the bispecific antibody is:

(i) a monoclonal antibody, a humanized antibody, or a chimeric antibody;

(ii) a full-length antibody; and/or

(iii) an IgG antibody.

16. The bispecific antibody of any one of claims 1-15, wherein the bispecific antibody comprises one or more heavy chain constant domains, wherein the one or more heavy chain constant domains are selected from a first CH1 ($CH1_1$) domain, a first CH2 ($CH2_1$) domain, a first CH3 ($CH3_1$) domain, a second CH1 ($CH1_2$) domain, second CH2 ($CH2_2$) domain, and a second CH3 ($CH3_2$) domain.

17. The bispecific antibody of claim 16, wherein at least one of the one or more heavy chain constant domains is paired with another heavy chain constant domain, wherein:

(a) the $CH3_1$ and $CH3_2$ domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the $CH3_1$ domain is positionable in the cavity or protuberance, respectively, in the $CH3_2$ domain; or

(b) the $CH2_1$ and $CH2_2$ domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the $CH2_1$ domain is positionable in the cavity or protuberance, respectively, in the $CH2_2$ domain.

18. The bispecific antibody of claim 17, wherein the bispecific antibody comprises the aglycosylation site mutation N297G or N297A, and wherein the anti-CD3 arm comprises the cavity and the anti-LYPD1 arm comprises the protuberance.

19. An isolated nucleic acid encoding the bispecific antibody of any one of claims 1-18.

20. A vector comprising the isolated nucleic acid of claim 19.

21. An isolated host cell comprising the vector of claim 20.

22. A method of producing the bispecific antibody of any one of claims 1-18, the method comprising culturing the host cell of claim 21 in a culture medium and recovering the bispecific antibody from the host cell or the culture medium.

23. An immunoconjugate comprising the bispecific antibody of any one of claims 1-18 and a cytotoxic agent.

24. A composition comprising the bispecific antibody of any one of claims 1-18 and a pharmaceutically acceptable carrier, excipient, or diluent.

25. The composition of claim 24, wherein the composition further comprises a PD-1 axis binding antagonist or an additional therapeutic agent.

26. The bispecific antibody of any one of claims 1-18 for use as a medicament.

27. The bispecific antibody of any one of claims 1-18 for use in (i) treating or delaying progression of a cell proliferative disorder in a subject in need thereof or (ii) enhancing immune function in a subject having a cell proliferative disorder.

28. The bispecific antibody for use of claim 27, wherein the cell proliferative disorder is a cancer.

29. The bispecific antibody for use of claim 28, wherein the cancer is a LYPD1-expressing cancer.

30. The bispecific antibody for use of any one of claims 26-29, wherein the bispecific antibody binds to (a) a CD3 molecule located on an immune effector cell and (b) a LYPD1 molecule located on a target cell other than the immune effector cell.

31. The bispecific antibody for use of claim 30, wherein the bispecific antibody activates the immune effector cell following binding to (a) and (b).

32. The bispecific antibody for use of any one of claims 26-31, wherein the bispecific antibody is formulated for administration at a dosage of about 0.01 mg/kg to about 10 mg/kg, about 0.1 mg/kg to about 10 mg/kg, or about 1 mg/kg.

33. The bispecific antibody for use of any one of claims 26-32, wherein the bispecific antibody is formulated for administration with a PD-1 axis binding antagonist and/or an additional therapeutic agent.

34. The bispecific antibody for use of claim 33, wherein the PD-1 axis binding antagonist is selected from the group consisting of a PD-1 binding antagonist, a PD-L1 binding antagonist, and a PD-L2 binding antagonist.

35. The bispecific antibody for use of claim 34, wherein the PD-1 axis binding antagonist is:

(i) a PD-L1 binding antagonist selected from the group consisting of: MPDL3280A, MDX-1105, and MEDI4736;

(ii) a PD-1 binding antagonist selected from the group consisting of MDX-1106 (nivolumab), MK-3475 (lambrolizumab), and AMP-224; or

(iii) a PD-L2 binding antagonist which is an antibody or an immunoadhesin.

36. The bispecific antibody for use of any one of claims 26-35, wherein the bispecific antibody is formulated for administration in combination with a glucocorticoid or an antibody-drug conjugate (ADC).

37. The bispecific antibody for use of any one of claims 26-36, wherein the bispecific antibody is formulated for administration subcutaneously, intravenously, intramuscularly, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally.

38. The bispecific antibody for use of any one of claims 27-37, wherein the subject is a human.

39. Use of the bispecific antibody of any one of claims 1-18 in the manufacture of a medicament.

40. The use of claim 39, wherein the medicament is for (i) treating or delaying progression of a cell proliferative disorder in a subject in need thereof or (ii) enhancing immune function in a subject having a cell proliferative disorder.

41. The use of claim 40, wherein the cell proliferative disorder is a cancer.

42. The use of claim 41, wherein the cancer is a LYPD1-expressing cancer.

43. The use of any one of claims 39-42, wherein the bispecific antibody binds to (a) a CD3 molecule located on an immune effector cell and (b) a LYPD1 molecule located on a target cell other than the immune effector cell.

44. The use of claim 43, wherein the bispecific antibody activates the immune effector cell following binding to (a) and (b).

45. The use of any one of claims 39-44, wherein the bispecific antibody is formulated for administration at a dosage of about 0.01 mg/kg to about 10 mg/kg, about 0.1 mg/kg to about 10 mg/kg, or about 1 mg/kg.

46. The use of any one of claims 39-45, wherein the medicament is formulated for use in combination with a PD-1 axis binding antagonist and/or an additional therapeutic agent.

47. The use of claim 46, wherein the PD-1 axis binding antagonist is selected from the group consisting of a PD-1 binding antagonist, a PD-L1 binding antagonist, and a PD-L2 binding antagonist.

48. The use of claim 47, wherein the PD-1 axis binding antagonist is:

(i) a PD-L1 binding antagonist selected from the group consisting of: MPDL3280A, MDX-1105, and MEDI4736;

(ii) a PD-1 binding antagonist selected from the group consisting of MDX-1106 (nivolumab), MK-3475 (lambrolizumab), and AMP-224; or

(iii) a PD-L2 binding antagonist which is an antibody or an immunoadhesin.

49. The use of any one of claims 39-48, wherein the medicament is formulated for use in combination with a glucocorticoid or an antibody-drug conjugate (ADC).

50. The use of any one of claims 39-49, wherein the medicament is formulated for administration to a subject subcutaneously, intravenously, intramuscularly, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally.

51. The use of any one of claims 40-50, wherein the subject is a human.

52. A kit comprising:

(a) the composition of claim 24 or 25; and

(b) a package insert comprising instructions for use of the composition to treat or delay progression of a cell proliferative disorder.

53. The kit of claim 52, wherein the cell proliferative disorder is a cancer.

54. The kit of claim 53, wherein the cancer is a LYPD1-expressing cancer.